Senti Biosciences Navigates Challenging Financial Landscape, Explores Strategic Options

Senti Biosciences, Inc., a clinical-stage biotechnology company developing next-generation cell and gene therapies, has faced a complex financial situation in recent quarters. The company’s latest financial report reveals both progress and challenges as it works to advance its pipeline of innovative treatments.

Financial Performance Overview

For the six months ended June 30, 2026, Senti Biosciences reported a net loss of $17.0 million, a significant improvement from the $28.8 million net loss recorded in the same period of 2025. This reduction in losses was driven by a number of factors:

• Collaboration Revenue: The company generated $33,000 in collaboration revenue from a related-party agreement, compared to no revenue in the prior-year period.

• Reduced R&D Expenses: Research and development expenses decreased by $6.3 million, from $19.3 million in the first half of 2025 to $13.0 million in 2026. This was primarily due to a reduction in external services and supplies costs related to the company’s lead product candidate, SENTI-202.

• Gain on Lease Modification: Senti Biosciences recorded a one-time gain of $6.9 million related to the amendment of its Alameda lease, which reduced the leased premises and corresponding future lease payments.

• Decreased G&A Costs: General and administrative expenses declined by $0.9 million, from $13.9 million in the first half of 2025 to $13.0 million in 2026, driven by reductions in personnel-related expenses, depreciation, and facilities costs.

Despite these improvements, the company continues to face significant financial challenges. As of June 30, 2026, Senti Biosciences had $6.5 million in cash and cash equivalents, down from $16.4 million at the end of 2025. The company’s accumulated deficit has grown to $375.5 million, and it used $21.7 million in cash for operating activities during the first six months of 2026.

Revenue and Profit Trends

Senti Biosciences has yet to generate any revenue from product sales, as its pipeline of cell and gene therapy candidates remains in the clinical and preclinical development stages. The company’s sole source of revenue during the reported periods was a collaboration agreement with a related party, BlueRock Therapeutics LP, which contributed $33,000 in the first half of 2026.

On the expense side, research and development (R&D) costs have been the primary driver of the company’s losses. R&D expenses accounted for $13.0 million, or 40%, of Senti Biosciences’ total operating expenses in the first six months of 2026. These costs are associated with advancing the company’s pipeline, including its lead candidate SENTI-202.

While R&D expenses decreased compared to the prior-year period, the company continues to invest heavily in its development programs. This is in line with its strategy of leveraging its synthetic biology platform to create novel cell and gene therapies. However, the significant R&D spending has contributed to the company’s ongoing net losses and cash burn.

General and administrative (G&A) expenses, which include costs related to personnel, professional services, and facilities, accounted for the remaining 60% of Senti Biosciences’ operating expenses in the first half of 2026. These costs declined slightly compared to the same period in 2025, but remain a substantial burden on the company’s financial resources.

The one-time gain of $6.9 million from the Alameda lease modification was a bright spot in the company’s financial performance, providing a much-needed boost to its bottom line. This transaction allowed Senti Biosciences to reduce its leased premises and corresponding future lease payments, improving its overall cost structure.

Strengths and Weaknesses

Strengths:

• Innovative Technology Platform: Senti Biosciences has developed a proprietary synthetic biology platform that enables the engineering of gene circuits to program next-generation cell and gene therapies. This technology has the potential to address major challenges in cancer treatment and other complex diseases.

• Promising Pipeline: The company’s lead product candidate, SENTI-202, is being developed as a CAR-NK cell therapy for oncology indications with high unmet need. The pipeline also includes earlier-stage programs targeting Rett Syndrome and tumor-infiltrating lymphocytes (TILs).

• Collaboration Agreements: Senti Biosciences has established a collaboration with BlueRock Therapeutics, a related party, which has provided some revenue and validation of the company’s technology.

• Lease Optimization: The Alameda lease modification allowed Senti Biosciences to significantly reduce its future lease obligations, improving its financial position.

Weaknesses:

• Lack of Revenue: As a clinical-stage company, Senti Biosciences has not yet generated any revenue from product sales, relying solely on collaboration agreements and financing activities to fund its operations.

• Substantial Losses and Cash Burn: The company has incurred significant net losses and used substantial amounts of cash in its operations, which is typical for a biotechnology company at this stage of development. However, Senti Biosciences’ financial situation remains precarious, with limited cash resources and an accumulated deficit of $375.5 million.

• Dependence on External Financing: Senti Biosciences will require substantial additional funding to support its ongoing operations and development activities. The company’s ability to raise capital on favorable terms, or at all, is critical to its future success.

• Regulatory and Clinical Risks: As with any biotechnology company, Senti Biosciences faces significant risks related to the successful completion of clinical trials, regulatory approvals, and the commercialization of its product candidates. Delays or setbacks in these areas could further strain the company’s financial resources.

Outlook and Future Prospects

Senti Biosciences’ financial future remains uncertain, as the company continues to navigate a challenging operating environment and search for additional sources of funding. The company’s ability to advance its pipeline and achieve long-term sustainability will depend on its success in securing new financing, potentially through equity or debt offerings, collaborations, or other strategic transactions.

The recent Merger Agreement with Celadon Partners, the company’s largest shareholder, represents a potential path forward. If approved by Senti Biosciences’ shareholders, the merger would result in Celadon acquiring the company’s existing business and pipeline, while the current public company would retain certain intellectual property, contracts, and early-stage development programs.

Under the terms of the Merger Agreement, Senti Biosciences’ shareholders would receive contingent value rights (CVRs) that could provide up to $60 million in additional payments upon the achievement of certain regulatory and sales milestones related to the SENTI-202 product candidate. This structure aims to provide potential upside for shareholders while also addressing the company’s immediate financial needs.

However, the completion of the merger remains subject to several conditions, including shareholder approval and the satisfaction of other closing requirements. If the merger is not consummated, Senti Biosciences will need to explore alternative financing options to sustain its operations and continue the development of its pipeline.

In the meantime, the company has taken steps to improve its financial position, such as the Alameda lease modification and the issuance of $10 million in convertible notes to an investor affiliated with Celadon. These transactions have provided some near-term relief, but the company’s long-term viability will depend on its ability to secure additional funding and achieve meaningful progress with its clinical programs.

Overall, Senti Biosciences faces significant challenges, but its innovative technology platform and promising pipeline of cell and gene therapies offer potential for long-term success. The company’s ability to navigate the current financial landscape and execute on its strategic plans will be crucial in determining its future trajectory.